Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
1,482
datasets available to search
ShareScore release 0.9.0
Dataset results
1,482 results for “adult vaccination”
Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Japanese Adults
ClinicalTrials.gov study NCT04498832. IPD Sharing: YES. Countries: 1. Publications: 1.
Study of Monovalent and Bivalent Recombinant Protein Vaccines Against COVID-19 in Adults 18 Years of Age and Older
ClinicalTrials.gov study NCT04904549. IPD Sharing: YES. Countries: 11. Publications: 1.
Study on an Investigational Yellow Fever Vaccine Compared With YF-VAX in Adults in the USA
ClinicalTrials.gov study NCT04942210. IPD Sharing: YES. Countries: 1. Publications: 0.
Misconceptions about COVID-19 vaccine among adults in Saudi Arabia and their associated factor
<p>It is of the utmost importance for the elements that influence public compliance to the COVID-19 vaccine to be assessed, including misconceptions, rumors, and conspiracy theories. Hence our study aimed to estimate the distribution of the most common misconceptions and their predictors in Saudi Arabia. We distributed an online questionnaire to participants who were 18 years or older at the time of the survey, which included four sections: demographic characteristics of participants, level of their education, their sources of information, and perception of participants regarding eleven of the most common misconceptions in the community.</p> <p>An evaluation of the relationships between different predictors and acceptance of these misconceptions was conducted using ordinal logistic regression; the most widely accepted misconception was that the vaccine has serious side effects, with 34.8% of participants reporting this.</p> <p><strong>Accepting this misinformation</strong> Factors that were significantly associated with acceptance or refusal of misconceptions were:</p> <p><span>Gender</span>, as females in this survey significantly accept rumors more than males (p<0.001);</p> <p><span>Educational level</span>, especially secondary school, was associated with a significant decrease in acceptance of misconceptions (p=0.001);</p> <p><span>Information source</span>. 60.5% of participants use social media as their primary source of information, and it was also a significant positive predictor of acceptance of misconceptions (p=0.034).</p> <p>It is of utmost importance to increase assurance in the safety of the vaccine, as it was the most accepted misconception, and to address the elements that affect believing rumors among the population.</p>
Contextualization of enablers and barriers for COVID-19 vaccine uptake among adult tuberculosis patients attending selected clinics in Nairobi County, Kenya
<p>Although vaccination is a cost-effective, equitable, and impactful public health intervention in curbing the spread of infectious disease, low uptake is a significant concern, especially among high-risk population groups. Nearly half of the population is unvaccinated in Nairobi, yet there is a shortage of vaccination information on vulnerable tuberculosis (TB) patients. The interplay of factors influences uptake, and protecting this vulnerable group and the general population from severe disease, hospitalization, and deaths is worthy. The purpose of this study is to determine the prevalence and individual-level enablers and barriers to COVID-19 vaccine uptake among adult TB patients attending selected clinics in Nairobi County, Kenya. This cross-sectional mixed-method study was conducted at TB clinics across six sub-counties in Nairobi County. It included 388 participants sampled from each clinic's TB register. Quantitative data was collected using a questionnaire, and qualitative data was collected through key informant interviews and focus group discussions. Quantitative data was analyzed using descriptive statistics (frequencies and percentages for categorical variables and mean standard deviation for continuous variables) and inferential statistics (logistic regression). Qualitative data was analyzed through deductive coding and thematic analysis. The prevalence of COVID-19 vaccination was 46.1%, with 38.1% receiving complete vaccination. Mistrust in vaccine management (adjusted odds ratio (aOR)= 0.075, 95% confidence interval (CI): 0.025-0.229, <em>p </em><0.001) was a significant barrier to COVID-19 vaccine uptake. Perceived covid-19 susceptibility (aOR = 2.901, 95% CI: 1.258-6.688, <em>p </em>= 0.012) and perceived covid-19 seriousness (aOR = 3.294, 95% CI: 1.130-9.604, <em>p </em>= 0.029) were significant enablers of COVID-19 vaccine uptake. Qualitative themes related to individual-level barriers and enablers of COVID-19 vaccine uptake were fear of side effects, stigma, myths, and mistrust in the messaging for barriers and desire to protect others and risk perception as enablers. The study revealed critical individual-level factors related to COVID-19 vaccine uptake.</p>
Search strategies for herpes zoster vaccination for adults
<p>The dataset includes the complete, reproducible search strategies for all literature databases searched during this project. The search strategies were designed to answer the following research questions:</p> <ul> <li>RQ 1 – What is the clinical efficacy and effectiveness of the currently licensed and approved recombinant vaccine for the prevention of herpes zoster and associated complications, in adults aged 50 years and older and in adults aged 18 and over who are at increased risk of herpes zoster?</li> <li>RQ 2 – What is the safety profile of the currently licensed and approved recombinant vaccine for the prevention of herpes zoster in adults aged 50 years and older and in adults aged 18 and over who are at increased risk of herpes zoster?</li> </ul> <p> </p>
Safety, Immunogenicity, and Relative Efficacy of H1N1 Vaccines in Adults Aged 18 Years and Older
ClinicalTrials.gov study NCT00979602. IPD Sharing: YES. Countries: 2. Publications: 1.
Safety and Immunogenicity Study of a Candidate Tuberculosis Vaccine in Human Immunodeficiency Virus (HIV)-Positive Adults
ClinicalTrials.gov study NCT01262976. IPD Sharing: Not stated. Countries: 1. Publications: 1.
A Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-19 in Healthy and Immunocompromised Adults
ClinicalTrials.gov study NCT04380701. IPD Sharing: NO. Countries: 1. Publications: 10.
A Phase I Study of Quadrivalent Human Papilloma Virus (HPV) (Types 6, 11, 16, 18) Recombinant Vaccine in HIV-Infected and HIV-Negative Pre-Adolescents, Adolescents, and Young Adults
ClinicalTrials.gov study NCT00798265. IPD Sharing: YES. Countries: 1. Publications: 3.
Safety, Tolerability and Immunogenicity Study of 3 Prime-boost Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo in Healthy Adults, Children and Human Immunodeficiency Virus Positive (HIV+) Adults
ClinicalTrials.gov study NCT02564523. IPD Sharing: Not stated. Countries: 4. Publications: 3.
Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine GSK1437173A in Adults With a Prior Episode of Herpes Zoster
ClinicalTrials.gov study NCT01827839. IPD Sharing: YES. Countries: 2. Publications: 1.
Safety and Immunogenicity of Plant-Derived Pfs25 VLP-FhCMB Malaria Transmission Blocking Vaccine in Healthy Adults
ClinicalTrials.gov study NCT02013687. IPD Sharing: UNDECIDED. Countries: 1. Publications: 1.
Safety and Immunogenicity of a Candidate Tuberculosis (TB) Vaccine in Adults With TB Disease
ClinicalTrials.gov study NCT01424501. IPD Sharing: YES. Countries: 2. Publications: 2.
Pivotal Study to Evaluate Safety and Immunogenicity of a Live-Attenuated Chikungunya Virus Vaccine Candidate in Adults
ClinicalTrials.gov study NCT04546724. IPD Sharing: NO. Countries: 1. Publications: 2.
Phase I Clinical Trial of a COVID-19 Vaccine in 18-60 Healthy Adults
ClinicalTrials.gov study NCT04313127. IPD Sharing: YES. Countries: 1. Publications: 1.
Safety and Immunogenicity of AERAS-402 in HIV-infected, Bacillus Calmette-Guerin (BCG)-Vaccinated Adults
ClinicalTrials.gov study NCT01017536. IPD Sharing: UNDECIDED. Countries: 1. Publications: 1.
A Phase IIb, Open-Label, Dose Ranging Study of 13-Valent Pneumococcal Conjugate Vaccine in Adults 55 Through 74 Years of Age Previously Vaccinated With 23-Valent Pneumococcal Polysaccharide Vaccine
ClinicalTrials.gov study NCT01654263. IPD Sharing: Not stated. Countries: 1. Publications: 1.
A Study to Evaluate a Range of Dose Levels and Vaccination Intervals of Ad26.COV2.S in Healthy Adults and Adolescents
ClinicalTrials.gov study NCT04535453. IPD Sharing: YES. Countries: 4. Publications: 2.
A Study to Evaluate the Safety of the Respiratory Syncytial Virus Vaccine MEDI7510 in Older Adults
ClinicalTrials.gov study NCT02115815. IPD Sharing: Not stated. Countries: 1. Publications: 1.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.